1989
DOI: 10.1212/wnl.39.9.1159
|View full text |Cite
|
Sign up to set email alerts
|

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assesment of Alzheimer's disease

Abstract: The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) has developed brief, comprehensive, and reliable batteries of clinical and neuropsychological tests for assessment of patients with the clinical diagnosis of Alzheimer's disease (AD). We administered these batteries in a standardized manner to more than 350 subjects with a diagnosis of AD and 275 control subjects who were enrolled in a nationwide registry by a consortium of 16 university medical centers. The tests selected for this study me… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

2
1,079
0
9

Year Published

1991
1991
2017
2017

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 3,486 publications
(1,090 citation statements)
references
References 0 publications
2
1,079
0
9
Order By: Relevance
“…All the patients with AD who were included in this investigation already had a diagnosis of probable AD, which was confirmed by way of the Consortium to Establish a Registry for Alzheimer's Disease 13 , and all subjects were treated with cholinesterase inhibitors. This study was approved by the Ethics Committee of our university hospital.…”
Section: Methods Participantsmentioning
confidence: 94%
“…All the patients with AD who were included in this investigation already had a diagnosis of probable AD, which was confirmed by way of the Consortium to Establish a Registry for Alzheimer's Disease 13 , and all subjects were treated with cholinesterase inhibitors. This study was approved by the Ethics Committee of our university hospital.…”
Section: Methods Participantsmentioning
confidence: 94%
“…The battery comprised tests previously validated for cross‐cultural settings 17, 18. The following domains were derived by summing standardized individual test scores: global/overall function (Community Screening Instrument for Dementia [CSID] cognitive assessment)19; verbal memory (immediate and delayed verbal recall [CERAD 10‐word]20), visual memory (picture recognition); fluency (animal naming21), processing speed (color trail‐making A and B22); and working memory (forward and backward digit span23). …”
Section: Methodsmentioning
confidence: 99%
“…We selected the Short Blessed Test (SBT) [26], a brief version of the Blessed Information-Memory-Concentration Test [27], as the brief cognitive assessment to identify and exclude patients with significant (SBT > 4) cognitive impairment [28]. The SBT is shorter than other cognitive assessments, such as the MMSE [29] and the MOCA [30].…”
Section: Methodsmentioning
confidence: 99%